IL6 and uveitis: Notably, two phase III trials, namely, MEERKAT (NCT05642312) and SANDCAT (NCT05642325), are currently underway to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of vamikibart, an anti-IL-6 monoclonal antibody, in patients with uveitis ME (Suhler et al., 2024).